San Diego, CA -- (SBWIRE) -- 04/27/2016 -- Chiasma Inc is under investigation over potential securities laws violations. The investigation was announced on behalf of investors in NASDAQ:CHMA shares in connection certain financial statements made by Chiasma Inc.

Investors who purchased shares of Chiasma Inc (NASDAQ:CHMA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements by Chiasma regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Chiasma Inc went public in July 2015 initial public stock offering. Chiasma Inc offered more than 6,300,000 shares of its common stock at $16.00 per share in connection with its initial public stock offering ("IPO").

On April 15, 2016, U.S. Food and Drug Administration ("FDA") reported its decision on Chiasma's acromegaly candidate, Mycappsa. The FDA issued a complete response letter and said that the new drug application (NDA) for its treatment of a rare ailment related to the pituitary gland was not ready for approval in its present form. Shares of Chiasma Inc (NASDAQ:CHMA) declined on April 20, 2016, to as low as $3.53 per share.

On April 25, 2016, NASDAQ:CHMA shares closed at $3.68 per share.

Those who purchased shares of Chiasma Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com